Barclays Lowers Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) to Equal Weight

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) was downgraded by analysts in Barclays equity research from an “overweight” rating to an “equal weight” rating in a rating issued to investors on Friday, The Fly reports.

Several other analysts also commented on the company. Societe Generale reaffirmed a “conservation” note on the shares of Fresenius Medical Care AG & Co. KGaA in a research note on Wednesday August 4th. The UBS Group reissued a “buy” note on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, July 20. Deutsche Bank Aktiengesellschaft reaffirmed a “custody” rating of shares in Fresenius Medical Care AG & Co. KGaA in a research report published on Wednesday, July 21. TheStreet reduced Fresenius Medical Care AG & Co. KGaA from a “b-” rating to a “c +” rating in a research report released on Friday, September 3. Finally, JPMorgan Chase & Co. downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underweight” rating in a research note on Friday. Two analysts rated the stock with a sell rating, eleven issued a conservation rating and five gave the company a buy rating. Based on data from MarketBeat.com, the company currently has an average rating of “Hold”.

Shares of Fresenius Medical Care AG & Co. KGaA traded at $ 1.56 on Friday, reaching $ 36.61. 1,428 shares of the company were traded in the hands, compared to its average volume of 357,899. Fresenius Medical Care AG & Co. KGaA has a 52-week low of $ 33.84 and a 52-week high of 44 , $ 13. The company has a quick ratio of 0.78, a current ratio of 1.05, and a debt ratio of 0.51. The company’s 50-day moving average is $ 40.03 and its 200-day moving average is $ 39.21. The stock has a market cap of $ 21.45 billion, a P / E ratio of 18.80, a PEG ratio of 7.76 and a beta of 1.28.

(A d)

Experts predict that 125 million electric vehicles will be in circulation by 2030. How will we provide manufacturers with the billions of pounds of lithium needed? This company may have the answer.

Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) last released its results on Friday, July 30. The company reported earnings per share of $ 0.46 for the quarter, missing the Thomson Reuters consensus estimate of $ 0.51 ($ 0.05). The company posted revenue of $ 5.20 billion in the quarter, compared to analysts’ estimates of $ 5.33 billion. Fresenius Medical Care AG & Co. KGaA reported a return on equity of 9.47% and a net margin of 5.74%. Equity research analysts predict that Fresenius Medical Care AG & Co. KGaA will post EPS of 2.07 for the current year.

Several institutional investors have recently increased or reduced their holdings in FMS. Advisor Partners LLC increased its stake in Fresenius Medical Care AG & Co. KGaA by 4.2% during the 2nd quarter. Advisor Partners LLC now owns 6,335 shares of the company valued at $ 263,000 after purchasing an additional 256 shares during the period. PNC Financial Services Group Inc. increased its position in Fresenius Medical Care AG & Co. KGaA by 1.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 21,893 shares of the company valued at $ 911,000 after purchasing an additional 259 shares during the last quarter. Quadrant Capital Group LLC increased its position in Fresenius Medical Care AG & Co. KGaA by 26.2% during the 1st quarter. Quadrant Capital Group LLC now owns 1,339 shares of the company valued at $ 49,000 after purchasing an additional 278 shares in the last quarter. Altfest LJ & Co. Inc. increased its position in Fresenius Medical Care AG & Co. KGaA by 6.2% during the 1st quarter. Altfest LJ & Co. Inc. now owns 6,268 shares of the company valued at $ 231,000 after purchasing 368 additional shares during the last quarter. Finally, MAI Capital Management strengthened its position in Fresenius Medical Care AG & Co. KGaA by 2.1% during the second quarter. MAI Capital Management now owns 17,893 shares of the company valued at $ 744,000 after purchasing 368 additional shares during the last quarter. 3.49% of the shares are currently held by institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA provides products and services to patients with chronic kidney disease. It also develops and manufactures a variety of healthcare products, including dialysis products and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Recommended Story: Commodities

The fly logo

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)

Should you invest $ 1,000 in Fresenius Medical Care AG & Co. KGaA now?

Before you consider Fresenius Medical Care AG & Co. KGaA, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat identified the five stocks that top analysts are quietly asking their clients to buy now before the broader market takes hold of … and Fresenius Medical Care AG & Co. KGaA was not on the list.

While Fresenius Medical Care AG & Co. KGaA currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Source link

Leave a Reply

Your email address will not be published.